Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13479810 | 0.83 | NSD2 (0.48) | MLYCDNSD2CA1CA2ALDH1A1 | |
| SCHEMBL10777010 | 0.82 | CA1 (0.48) | MLYCDNSD2CA1CA2ALDH1A1 | |
| SCHEMBL10933810 | 0.81 | NSD2 (0.55) | MLYCDNSD2CA1CA2ALDH1A1 | |
| SCHEMBL310054 | 0.80 | GSK3B (0.50) | ALDH1A1GSK3BPOLBTSHR | |
| SCHEMBL13151106 | 0.79 | NSD2 (0.54) | MLYCDNSD2CA1CA2ALDH1A1 | |
| SCHEMBL1011694 | 0.79 | PIK3CA (0.42) | MLYCDNSD2CA1CA2 | |
| SCHEMBL1303906 | 0.77 | MLYCD (0.57) | MLYCDCA1CA2ALDH1A1MAPT | |
| SCHEMBL22531823 | 0.77 | MLYCD (0.57) | MLYCDCA1CA2ALDH1A1POLB | |
| SCHEMBL870352 | 0.77 | MLYCD (0.57) | MLYCDALDH1A1MAPTGSK3BKMT2A | |
| SCHEMBL1012521 | 0.77 | MLYCD (0.57) | MLYCDALDH1A1MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10391093-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3057422-B1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100204493-A1 | Process for the Preparation of Escitalopram | CIPLA LIMITED (IN) | 2010-08-12 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| WO-2008142379-A2 | PROCESS FOR THE PREPARATION OF ESCITALOPRAM VIA DESMETHYLCITALOPRAM, OPTICAL RESOLUTION AND METHYLATION OF THE S-ISOMER | CIPLA LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | PSEN1, PSEN2, MAPT | MLYCD 3024/4885NSD2 2466/4885CA1 157/4885 |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | PSEN1, PSEN2, MAPT | MLYCD 3024/4885NSD2 2466/4885CA1 157/4885 |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | MLYCD 1531/4885NSD2 2953/4885CA1 1632/4885 |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | MLYCD 3220/4885NSD2 1088/4885CA1 4525/4885 |
| US-10201546-B2 | Quinolinyl modulators of RORγt | RORC, RORB, RORA | MLYCD 4743/4885NSD2 2614/4885CA1 3821/4885 |
| US-20100204493-A1 | Process for the Preparation of Escitalopram | SLC6A4, SLC6A3, HTR3B | MLYCD 2551/4885NSD2 1727/4885CA1 3989/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | MLYCD 1547/4885NSD2 2965/4885CA1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.